Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 18/20 | 0.33 |
| ▸ | FNTB | P49356 | 18/20 | 0.33 |
| ▸ | HRAS | P01112 | 1/20 | 0.32 |
| ▸ | KRAS | P01116 | 1/20 | 0.32 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | GFRA3 | O60609 | 1/20 | 0.31 |
| ▸ | RET | P07949 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30856753 | 1.00 | FNTA (0.33) | FNTAFNTBHRASKRASABCB1 | |
| SCHEMBL30702240 | 1.00 | FNTA (0.33) | FNTAFNTBHRASKRASABCB1 | |
| SCHEMBL10287035 | 0.89 | POLB (0.36) | FNTAFNTBHRASKRASABCB1 | |
| SCHEMBL18650419 | 0.79 | AKR1B1 (0.34) | FNTAFNTBHTTKMT2A | |
| SCHEMBL24729873 | 0.78 | GFRA3 (0.31) | GFRA3RET | |
| SCHEMBL12696395 | 0.78 | EPAS1 (0.34) | GFRA3RET | |
| SCHEMBL568654 | 0.78 | TRPM5 (0.36) | FNTAFNTBGFRA3RET | |
| SCHEMBL23937987 | 0.78 | DRD2 (0.36) | FNTAFNTBGFRA3RET | |
| SCHEMBL14616893 | 0.78 | HTT (0.35) | FNTAFNTBHRASKRASABCB1 | |
| SCHEMBL9403366 | 0.78 | FNTA (0.33) | FNTAFNTBHRASKRASABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12509431-B2 | 1,4-dihydroquinazolinone compounds and uses thereof | EDGEWISE THERAPEUTICS, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-20250361213-A1 | 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS INC (US) | 2025-11-27 | — | — | US | disclosed |
| EP-4594307-A1 | 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20250154111-A1 | 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. | 2025-05-15 | — | — | US | disclosed |
| US-20250059173-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2025-02-20 | — | — | US | disclosed |
| EP-4491622-A2 | CARDIAC SARCOMERE INHIBITORS | Cytokinetics, Inc. (US) | 2025-01-15 | — | — | EP | disclosed |
| US-20240400544-A1 | N-(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDE ANALOGS AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-12-05 | — | — | US | disclosed |
| EP-3740481-B9 | DIHYDROBENZOFURAN AND INDEN ANALOGS AS CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS INC (US) | 2024-10-23 | — | — | EP | disclosed |
| US-12065436-B2 | Cardiac sarcomere inhibitors | CYTOKINETICS, INC. (US) | 2024-08-20 | — | — | US | disclosed |
| EP-3740481-B1 | DIHYDROBENZOFURAN AND INDEN ANALOGS AS CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS INC (US) | 2024-06-26 | — | — | EP | disclosed |
| WO-2019144041-A1 | DIHYDROBENZOFURAN AND INDEN ANALOGS AS CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. (US) | 2019-07-25 | — | — | WO | disclosed |
| EP-3076959-B1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2018-07-04 | — | — | EP | disclosed |
| US-9957219-B2 | Antidiabetic bicyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2018-05-01 | — | — | US | disclosed |
| WO-2017188288-A1 | 5-SUBSTITUTED AZABENZIMIDAZOLE DERIVATIVE HAVING AMPK ACTIVATION ACTION | 塩野義製薬株式会社 | 2017-11-02 | — | — | WO | disclosed |
| EP-3076959-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2016-10-12 | — | — | EP | disclosed |
| US-20160280626-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2016-09-29 | — | — | US | disclosed |
| WO-2015084692-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2015-06-11 | — | — | WO | disclosed |
| EP-2668155-B1 | NEW ARYL-BENZOCYCLOALKYL AMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-11-26 | — | — | EP | disclosed |
| US-20130018055-A1 | NEW ARYL-BENZOCYCLOALKYL AMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-01-17 | — | — | US | disclosed |
| US-20130018055-A1 | NEW ARYL-BENZOCYCLOALKYL AMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12065436-B2 | Cardiac sarcomere inhibitors | TNNI3, TNNT2, MYLK2 | FNTA 3967/4885FNTB 2359/4885HRAS 4062/4885 |
| US-12509431-B2 | 1,4-dihydroquinazolinone compounds and uses thereof | TNNT2, TNNI3, TNNC1 | FNTA 3386/4885FNTB 1736/4885HRAS 1628/4885 |
| US-20160280626-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | GPR119, GPR65, GLP1R | FNTA 1288/4885FNTB 1683/4885HRAS 3120/4885 |
| US-20130018055-A1 | NEW ARYL-BENZOCYCLOALKYL AMIDE DERIVATIVES | CYP1A1, AHR, CYP1B1 | FNTA 3399/4885FNTB 3201/4885HRAS 200/4885 |
| US-20250154111-A1 | 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, SDHA | FNTA 2280/4885FNTB 1381/4885HRAS 3550/4885 |
| US-20250361213-A1 | 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, SDHA | FNTA 2280/4885FNTB 1381/4885HRAS 3550/4885 |
| US-20250059173-A1 | CARDIAC SARCOMERE INHIBITORS | TNNI3, TNNT2, MYLK2 | FNTA 3967/4885FNTB 2359/4885HRAS 4062/4885 |
| US-20240400544-A1 | N-(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDE ANALOGS AS MODULATORS OF SODIUM CHANNELS | TRPV1, SCN1A, SCN2A | FNTA 2781/4885FNTB 1892/4885HRAS 826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.